Hypertension Trial, Recruiting NCT06152614 Sponsor: Indiana University Condition: Hypertension
Back to Hypertension

Hypertension Trial, Recruiting

NCT06152614
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who speak and understand English fluently
  • People who live in Marion County
  • People between the ages of 35 and 75
  • People who identify as non-Hispanic and Black, African-American, or biracial including African-American
  • People who had a blood pressure reading of 140 or higher (top number) at a primary care visit in the past 12 months
  • People who are able to see and read street signs (based on self-report)
  • People who have stable housing with their own access to a kitchen that has a working stove or hotplate, oven, refrigerator, and freezer (based on self-report)
  • People who can manage everyday tasks largely on their own, based on a standard questionnaire about daily activities
  • People who score well on a short memory and thinking screening test
  • People who do less than 20 minutes of moderate or vigorous physical activity on a typical day
  • People who are cleared to exercise safely, either through a short exercise screening tool or with approval from their primary care doctor
  • People whose blood pressure measures 130 or higher (top number) on average across three readings taken by research staff under standardised conditions

Who may not be able to join:

  • People who live in a nursing home
  • People with a diagnosis of dementia, Alzheimer's disease, mild cognitive impairment, Parkinson's disease, a brain tumour, brain infection, or brain surgery within the last 10 years that left lasting symptoms or difficulties with learning, memory, or communication; cancer with a short life expectancy; current chemotherapy or radiation treatment; or psychosis, schizophrenia, or bipolar disorder
  • People whose medical records show certain specific types of high blood pressure-related heart or kidney disease (confirm with trial site)
  • People who are currently taking or have previously been prescribed the medications donepezil, memantine, rivastigmine, or galantamine (medications commonly used for memory conditions)
  • People who drink 8 or more alcoholic drinks per week (for women) or 15 or more per week (for men)
  • People whose medical records indicate non-marijuana drug use or misuse
  • People who plan to move out of the area during the study period
  • People whose schedules conflict with the intervention timetable
  • People who are unwilling to use a touchscreen device
  • People who are unwilling to participate in video calls
  • People whose ability to communicate, level of daily functioning, or other conditions would interfere with taking part in the study activities (as assessed by the examiner)
  • People who are unable to provide informed consent
  • People who are currently participating in a lifestyle change or weight loss programme (such as Weight Watchers or similar)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Daniel O Clark, PhD, Indiana University

Phone: 317-274-9292

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
28 November 2023
Est. completion
31 May 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Cognitive function composite score as measured by individually-administered tests of psychomotor speed, complex sequencing, semantic fluency, interference and list learning and delayed recall at Week 28.; Cognitive function composite score as measured by individually-administered tests of psychomotor speed, complex sequencing, semantic fluency, interference and list learning and delayed recall at Week 52.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov